ABAX - Abaxis, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
83.29
-0.06 (-0.07%)
At close: 4:00PM EDT

83.29 0.00 (0.00%)
After hours: 4:16PM EDT

Stock chart is not supported by your current browser
Previous Close83.35
Open83.25
Bid82.18 x 800
Ask83.62 x 1000
Day's Range83.22 - 83.32
52 Week Range43.66 - 83.98
Volume60,121
Avg. Volume316,890
Market Cap1.905B
Beta2.29
PE Ratio (TTM)71.19
EPS (TTM)1.17
Earnings DateJul 25, 2018 - Jul 30, 2018
Forward Dividend & Yield0.72 (0.86%)
Ex-Dividend Date2018-05-31
1y Target Est71.00
Trade prices are not sourced from all markets
  • See what the IHS Markit Score report has to say about Abaxis Inc.
    Markit11 hours ago

    See what the IHS Markit Score report has to say about Abaxis Inc.

    Additionally, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on July 16. Over the last one-month, outflows of investor capital in ETFs holding ABAX totaled $1.78 billion.

  • GlobeNewswire20 hours ago

    Rigrodsky & Long, P.A. Files Class Action Suit Against Abaxis, Inc.

    Rigrodsky & Long, P.A. announces that it has filed a class action complaint in the United States District Court for the Northern District of California on behalf of holders of Abaxis, Inc. (“Abaxis”) (ABAX) common stock in connection with the proposed acquisition of Abaxis by Zoetis, Inc. and its affiliate (“Zoetis”) announced on May 16, 2018 (the “Complaint”).  The Complaint, which alleges violations of the Securities Exchange Act of 1934 against Abaxis and its Board of Directors (the “Board”), is captioned Kent v. Abaxis, Inc., Case No. 3:18-cv-03834 (N.D. Cal.).

  • Abaxis (ABAX) and Zoetis Merger Deal Crosses HRS Hurdle
    Zacks8 days ago

    Abaxis (ABAX) and Zoetis Merger Deal Crosses HRS Hurdle

    With the adoption of Abaxis' (ABAX) point-of-care diagnostic instruments post acquisition, the combined entity's veterinary diagnostics category should grow faster than the animal health industry.

  • ACCESSWIRE8 days ago

    Wired News - Zoetis Announces HSR Clearance for Acquisition of Animal Health Company Abaxis

    LONDON, UK / ACCESSWIRE / July 10, 2018 / If you want access to our free research report on Zoetis Inc. (NYSE: ZTS), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ZTS as the Company's latest news hit the wire. On July 06, 2018, the Company announced that it has completed the acquisition of Abaxis, Inc. (NASDAQ: ABAX), which is a leader in the development, manufacture, and marketing of diagnostic instruments for veterinary point-of-care services, for $83.00 per share in cash, or approximately $2.0 billion in total.

  • Top Ranked Momentum Stocks to Buy for July 9th
    Zacks9 days ago

    Top Ranked Momentum Stocks to Buy for July 9th

    Top Ranked Momentum Stocks to Buy for July 9th

  • Zoetis and Abaxis Announce Antitrust Clearance for Merger
    Market Realist9 days ago

    Zoetis and Abaxis Announce Antitrust Clearance for Merger

    On July 6, Zoetis (ZTS) and Abaxis (ABAX) announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act.

  • Zoetis and Abaxis Announce HSR Clearance for Zoetis’ Acquisition of Abaxis
    Business Wire12 days ago

    Zoetis and Abaxis Announce HSR Clearance for Zoetis’ Acquisition of Abaxis

    Zoetis Inc. (ZTS) and Abaxis, Inc. (ABAX) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), in connection with Zoetis’ previously-announced acquisition of Abaxis for US $83.00 per share in cash, or approximately $2.0 billion in aggregate. The expiration of the waiting period under the HSR Act satisfies one of the conditions necessary for the consummation of the transaction. The transaction is subject to other customary closing conditions, including the approval of Abaxis shareholders.

  • Here's Why You Should Add Abaxis (ABAX) to Your Portfolio
    Zacks19 days ago

    Here's Why You Should Add Abaxis (ABAX) to Your Portfolio

    We are upbeat about Abaxis' (ABAX) solid consumable and instrument sales growth along with strength in the medical and veterinary market segments.

  • Cardiovascular Systems (CSII) in Focus: Stock Moves 7.7% Higher
    Zacks20 days ago

    Cardiovascular Systems (CSII) in Focus: Stock Moves 7.7% Higher

    Cardiovascular Systems (CSII) was a big mover last session, as the company saw its shares rise nearly 8% on the day.

  • See what the IHS Markit Score report has to say about Abaxis Inc.
    Markit25 days ago

    See what the IHS Markit Score report has to say about Abaxis Inc.

    Index (PMI) data, output in the Healthcare sector is rising. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way.

  • Abaxis Inc (NASDAQ:ABAX): What Are The Future Prospects?
    Simply Wall St.27 days ago

    Abaxis Inc (NASDAQ:ABAX): What Are The Future Prospects?

    Since Abaxis Inc (NASDAQ:ABAX) released its earnings in March 2018, analysts seem fairly confident, as a 32.86% increase in profits is expected in the upcoming year, compared with the pastRead More...

  • See what the IHS Markit Score report has to say about Abaxis Inc.
    Markitlast month

    See what the IHS Markit Score report has to say about Abaxis Inc.

    The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.

  • PR Newswirelast month

    SHAREHOLDER ALERT: Monteverde & Associates PC Announces An Investigation Of Abaxis, Inc. - ABAX

    NEW YORK , June 5, 2018 /PRNewswire/ --  Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a national securities firm headquartered at the Empire State Building in New York ...

  • PR Newswirelast month

    Lifshitz & Miller LLP Announces Investigation of Abaxis, Inc., AeroVironment, Inc., Gramercy Property Trust, Mitel Networks Corporation, Molina Healthcare, Inc., Rockwell Medical, Inc., and Symantec Corporation

    NEW YORK , June 5, 2018 /PRNewswire/ -- Abaxis, Inc. (ABAX) Lifshitz & Miller  announces investigation into possible breaches of fiduciary duties in connection with the proposed sale of Abaxis to Zoetis ...

  • Abaxis Inc (NASDAQ:ABAX): Poised For Long-Term Success?
    Simply Wall St.2 months ago

    Abaxis Inc (NASDAQ:ABAX): Poised For Long-Term Success?

    The latest earnings release Abaxis Inc’s (NASDAQ:ABAX) announced in March 2018 showed that the business endured a immense headwind with earnings deteriorating by -17.09%. Below, I’ve presented key growth figuresRead More...

  • Business Wire2 months ago

    Robbins Arroyo LLP: Acquisition of Abaxis, Inc. (ABAX) by Zoetis Inc. (ZTS) May Not Be in Shareholders' Best Interests

    Shareholder rights attorneys at Robbins Arroyo LLP are investigating the proposed acquisition of Abaxis, Inc. (ABAX) by Zoetis Inc. (ZTS). On May 16, 2018, the two companies announced the signing of a definitive merger agreement pursuant to which Zoetis will acquire Abaxis. Under the terms of the agreement, Abaxis shareholders will receive $83.00 in cash for each share of Abaxis common stock.

  • Benzinga2 months ago

    Benzinga's Daily Biotech Pulse: AstraZeneca's Q1, Novartis-Amgen Migraine Drug Approved

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 17) Abaxis Inc (NASDAQ: ABAX ) (rallying for second straight session ...

  • PR Newswire2 months ago

    WeissLaw LLP Investigates Abaxis Inc.

    WeissLaw is investigating whether ABAX's Board acted to maximize shareholder value prior to entering into the agreement.  Notably, at least one analyst set a target price of $90.00 per share, or $7.00 above the offer price.  Additionally, ABAX recently announced positive financial results.  It reported revenue of $67.9 million, representing an increase of 17% when compared to the figures reported in the same period of the previous year.

  • Abaxis (ABAX) to be Acquired by Zoetis, Shares All-Time High
    Zacks2 months ago

    Abaxis (ABAX) to be Acquired by Zoetis, Shares All-Time High

    Post takeover of Abaxis' (ABAX) point-of-care diagnostic instruments, Zoetis expects the consolidated company's veterinary diagnostics category to speed up growth over the animal health industry.

  • Company News For May 17, 2018
    Zacks2 months ago

    Company News For May 17, 2018

    Companies In The News are: FOXA,IQV,ABAX,ZTS,TEVA,BRK.B

  • Zoetis (ZTS) Inks Deal to Acquire Abaxis for $2 Billion
    Zacks2 months ago

    Zoetis (ZTS) Inks Deal to Acquire Abaxis for $2 Billion

    Zoetis (ZTS) inks a definitive deal to acquire Caifornia-based Abaxis, for $83 per share in cash or a total of $2 billion.

  • Benzinga2 months ago

    Benzinga's Daily Biotech Pulse: ASCO Abstracts, Fibrocell, Ispen And More

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech Stocks Hitting 52-week highs on May 16) Abaxis Inc (NASDAQ: ABAX ) (announced a deal to be bought ...

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Stocks to Watch: Abaxis, Inc. and Cesca Therapeutics

    Shares of Abaxis hit an all-time high however after Wall Street learned that top animal health company Zoetis would be acquiring Abaxis for $83 a share. Abaxis, Inc. shares closed up 16.15% on Wednesday and hit an all-time high of $83.78 during intra-day trading. It was an exciting day for the company after it was announced that top animal health company Zoetis would be acquiring it for $1.9 billion.

  • ACCESSWIRE2 months ago

    SHAREHOLDER NOTICE: Brodsky & Smith, LLC Announces an Investigation of Abaxis, Inc. - ABAX

    BALA CYNWYD, PA / ACCESSWIRE / May 16, 2018 / Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Abaxis, Inc. ("Abaxis" or "the Company") (NASDAQ:ABAX News) for possible breaches of fiduciary duty and other violations of federal and state law in connection with the sale of the Company to Zoetis Inc. ("Zoetis"). Under the terms of the transaction, Abaxis shareholders will receive only $83.00 in cash for each share of Abaxis stock they own. The investigation concerns whether the Board of Abaxis breached their fiduciary duties to shareholders and whether Zoetis is underpaying for the Company.

  • The Wall Street Journal2 months ago

    [$$] Zoetis to Buy Veterinary-Diagnostics Company Abaxis for $2 Billion

    Animal-health company Zoetis Inc. has agreed to buy Abaxis Inc., a maker of veterinary-diagnostics equipment, in a deal valued at about $2 billion. Zoetis has offered $83 a share in cash for Abaxis, about a 16% premium to Abaxis’s closing price Tuesday. The companies said Wednesday the deal would grow Zoetis’s presence in veterinary diagnostics, a sector that has had an annual compound growth rate of about 10% for the past three years.